Abbott Gains in Nutrition With Adult Segment Leading Growth

Abbott Laboratories' (ABT) Nutrition business is demonstrating robust growth, primarily driven by its adult segment which posted 6.6% organic growth in Q2 2025 amid strong global demand for brands like Ensure and Glucerna. This expansion aligns with increasing health consciousness and rising non-communicable diseases, contributing to a projected $704.28 billion global nutritional supplements market by 2030. ABT shares have significantly outperformed year-to-date, climbing 16.5% against the industry's 5.9% and the S&P 500's 9.6%, and the stock trades at a discounted forward Price-to-Sales multiple of 4.89x compared to the industry average of 5.56x, despite a recent marginal downward revision in 2025 EPS estimates.

Analysis

Abbott Laboratories' (ABT) Nutrition segment is demonstrating robust performance, underpinned by its Adult Nutrition division which reported 6.6% organic growth in Q2 2025. This growth is fueled by strong global demand for its market-leading brands Ensure and Glucerna, capitalizing on a broader market trend toward health consciousness and a projected 6.42% CAGR for the global nutritional supplements market through 2030. While the company experiences some softness in international pediatric markets, its U.S. pediatric brand, Similac, maintains a strong domestic position. This fundamental strength is reflected in its stock performance, with a 16.5% year-to-date surge that significantly outpaces both the industry's 5.9% and the S&P 500's 9.6% growth. Despite this outperformance, the stock trades at a forward 12-month Price-to-Sales multiple of 4.89x, a discount to the industry average of 5.56x. A minor 0.2% downward revision in the 2025 EPS estimate represents a negligible headwind against an otherwise positive operational and market backdrop.

Key Decisions for Investors

• Given the strong organic growth in the Nutrition segment, significant stock outperformance, and a valuation that remains below the industry average, investors may view the current fundamentals as supportive of a continued long position.
• It is crucial to monitor the performance of the pediatric nutrition business in international markets, as any worsening of the noted softness could impact overall segment growth.
• Investors should weigh the company's strong execution and market position against the competitive landscape, which includes formidable peers like Nestlé and Danone, and watch for any signs of margin pressure or market share erosion.